CRG-101

N/A

Report date: 2025/03/20 13:33:40

Base Information

Drug NameCRG-101
Drug Alias NameiPSC衍生异体角膜内皮细胞CRG-101
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsFuchs' Endothelial DystrophyCorneal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Celregen Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Celregen Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsFuchs' Endothelial DystrophyCorneal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A